Cardiogenic shock resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 45: Line 45:
{{Family tree | | | | | | | | | | | | | | | | B01 | | | | | | | | |B01=<div style="float: center; text-align: center;">'''ABCD'''</div><div style="float: left; text-align: left; height: 10em; width: 17em"> ❑ Secure '''airway''' <br>❑ '''O2''' <br>❑ 2 wide bore IV access <br>❑ 12-lead '''ECG''' <br>❑ '''CXR''' <br>❑ '''Arterial''' line & '''Swan ganz''' catheter</div>}}
{{Family tree | | | | | | | | | | | | | | | | B01 | | | | | | | | |B01=<div style="float: center; text-align: center;">'''ABCD'''</div><div style="float: left; text-align: left; height: 10em; width: 17em"> ❑ Secure '''airway''' <br>❑ '''O2''' <br>❑ 2 wide bore IV access <br>❑ 12-lead '''ECG''' <br>❑ '''CXR''' <br>❑ '''Arterial''' line & '''Swan ganz''' catheter</div>}}
{{Family tree | | | | | | | | | | | | | | | | |!| | | | | | | | | | }}
{{Family tree | | | | | | | | | | | | | | | | |!| | | | | | | | | | }}
{{Family tree | | | | | | | | | | | | | | | | B02 | | | | | | |B02= <div style="float: center; text-align: center;">'''Hemodynamic optimization'''</div><div style="float: left; text-align: left; height: 8em; width: 13em"><br>❑ '''Fluid therapy'''(guided by PCWP,SaO2,CO)<br>❑ '''Contributing''' factors(-ve inotropes,diuretics)<br>❑ '''Vasopressors'''  (norepinephrine,dopamine)<br>❑ Correct '''Acidosis''' (affect vasopressors)<br>❑ Correct '''Hypoxemia''' (affect vasopressors)<br>❑ '''Medications''' (aspirin,heparin,GP IIb/IIIa)}}
{{Family tree | | | | | | | | | | | | | | | | B02 | | | | | | |B02= <div style="float: center; text-align: center;">'''Hemodynamic optimization'''</div><div style="float: left; text-align: left; height: 17em; width: 20em">❑ '''Fluid therapy'''(guided by PCWP,SaO2,CO)<br>❑ '''Contributing''' factors(-ve inotropes,diuretics)<br>❑ '''Vasopressors'''  (norepinephrine,dopamine)<br>❑ Correct '''Acidosis''' (affect vasopressors)<br>❑ Correct '''Hypoxemia''' (affect vasopressors)<br>❑ '''Medications''' (aspirin,heparin,GP IIb/IIIa)</div>}}
{{Family tree | | | | | | | | | | | | | | | | |!| | | | | | | | | | }}
{{Family tree | | | | | | | | | | | | | | | | |!| | | | | | | | | | }}
{{Family tree | | | | | | |,|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|.| | }}
{{Family tree | | | | | | |,|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|.| | }}
Line 52: Line 52:
{{Family tree | | | | | | D01 | | | | | | | | D02 | | | | | | | D03 | |D01= '''STEMI''' |D02= '''Focused cardiac ultrasound''' <br> rule out '''Acute valvular lesions''' |D03= Heart failure }}
{{Family tree | | | | | | D01 | | | | | | | | D02 | | | | | | | D03 | |D01= '''STEMI''' |D02= '''Focused cardiac ultrasound''' <br> rule out '''Acute valvular lesions''' |D03= Heart failure }}
{{Family tree | | | | | | |!| | | | |,|-|-|-|-|+|-|-|-|.| | | |!| | | }}   
{{Family tree | | | | | | |!| | | | |,|-|-|-|-|+|-|-|-|.| | | |!| | | }}   
{{Family tree | | | | | | E01 | | | E02 | | | E05 | | E04 | | E03 | |E01= Focused cardiac ultrasound to <br> associated valvular causes '''††''' |E02= '''*Pump failure RV/LV'''<br> <br>'''*High risk NSTEMI‡''' |E05= '''Acute severe MR'''<br>'''VSR'''<br> '''Critical AS,MS''' |E04= '''Aortic dissection'''<br>'''Tamponade''' |E03=<div style="float: center; text-align: center;"> Treatment of '''heart failure'''</div><div style="float: left; text-align: left; height: 5em; width: 13em"> <br>❑ '''Oxygen''' <br>❑ '''Diuretics''' <br>❑ '''Morphine''' <br>❑ '''Vasodilators'''</div>}}
{{Family tree | | | | | | E01 | | | E02 | | | E05 | | E04 | | E03 | |E01= Focused cardiac ultrasound to <br> associated valvular causes '''††''' |E02= '''*Pump failure RV/LV'''<br> <br>'''*High risk NSTEMI‡''' |E05= '''Acute severe MR'''<br>'''VSR'''<br> '''Critical AS,MS''' |E04= '''Aortic dissection'''<br>'''Tamponade''' |E03=<div style="float: center; text-align: center;"> Treatment of '''heart failure'''</div><div style="float: left; text-align: left; height: 5em; width: 13em">❑ '''Oxygen''' <br>❑ '''Diuretics''' <br>❑ '''Morphine''' <br>❑ '''Vasodilators'''</div>}}
{{Family tree | | | | |,|-|^|-|.| | |!| | | | |!| | | |!| | }}
{{Family tree | | | | |,|-|^|-|.| | |!| | | | |!| | | |!| | }}
{{Family tree | | | | |!| | | F01 | |!| | | | F03 | | |!| |F01= PCI capable center | |F03= '''IABP''' }}
{{Family tree | | | | |!| | | F01 | |!| | | | F03 | | |!| |F01= PCI capable center | |F03= '''IABP''' }}

Revision as of 02:37, 29 December 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overview

Cardiogenic shock is characterized by end organ failure due to systemic hypoperfusion resulting from cardiac failure. Cardiogenic shock is defined by the following hemodymanic parameters:
1- Persistent hypotension:

AND

2- Severe decrease in the cardiac index (CI):

  • CI <1.8 L/min/m2 without support, or
  • CI <2.0 to 2.2 L/min/m2 with support

AND

3- Adequate or elevated filling pressure:

  • Left ventricular end-diastolic pressure >18 mm Hg, or
  • Right ventricular end-diastolic pressure >10 to 15 mm Hg

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Cardiogenic shock is a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

Management

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Shock
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABCD
❑ Secure airway
O2
❑ 2 wide bore IV access
❑ 12-lead ECG
CXR
Arterial line & Swan ganz catheter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hemodynamic optimization
Fluid therapy(guided by PCWP,SaO2,CO)
Contributing factors(-ve inotropes,diuretics)
Vasopressors (norepinephrine,dopamine)
❑ Correct Acidosis (affect vasopressors)
❑ Correct Hypoxemia (affect vasopressors)
Medications (aspirin,heparin,GP IIb/IIIa)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG evidence of STEMI
 
 
 
 
 
 
 
ECG inconclusive
No ST/Limited ST/delayed CS
 
 
 
 
 
 
ECG: - ve
Clinical history of HF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STEMI
 
 
 
 
 
 
 
Focused cardiac ultrasound
rule out Acute valvular lesions
 
 
 
 
 
 
Heart failure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Focused cardiac ultrasound to
associated valvular causes ††
 
 
*Pump failure RV/LV

*High risk NSTEMI‡
 
 
Acute severe MR
VSR
Critical AS,MS
 
Aortic dissection
Tamponade
 
Treatment of heart failure
Oxygen
Diuretics
Morphine
Vasodilators
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCI capable center
 
 
 
 
 
 
IABP
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCI Non-capable center
 
 
 
Urgent PCI
 
 
 
 
 
Surgical correction
Valve surgery ± CABG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If 1-2 vessels
do PTCA
 
If severe lesion &
3 vessels do CABG
 
 
Transfer to PCI center¶
< 90 min
 
Transfer to PCI center
> 90 min
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urgent Transfer to PCI
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrombolytics
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Get stable
 
Still Non stable
* Hypotension
* ECG evidence
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transfer to PCI center within 3-24 hrs after Thrombolytics
 
IABP+
Urgent Transfer to PCI center
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Still Cardiogenic shock
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ventricular Assist Device
VAD
 
 
 
 
 
 


New ST elevation at the J point in at least 2 contiguous leads of 2 mm in men or 1.5 mm in women in leads V2-V3 and/or of 1 mm in other contiguous chest leads or the limb leads.

†† Early focused cardiac ultrasound should be done before PCI as long as the patient is not crashing, as it may change the treatment course.

High risk NSTEMI is when Non ST-elevation MI is associated with

  • Hemodynamic instability or cardiogenic shock
  • Severe left ventricular dysfunction or heart failure
  • Sustained ventricular arrhythmias
  • Recurrent or persistent rest angina despite intensive medical therapy
  • New or deteriorating mitral regurgitation
  • New ventricular septal defect

Door To Baloon, D2B

Do's

  • 250 mL of isotonic saline should be given empirically as an intravenous volume challenge before the right heart catheterization in patients with suspected CS as long as no clinical evidence of respiratory distress or radiological evidence of pulmonary congestion.
  • Correct metabolic acidosis caused by global tissue hypoperfusion, as acidosis can significantly reduce the responsiveness of the vasopressors.[3]
  • Monitor the hypovolemic state and hemodynamic status as cardiogenic shock occurs in 5-8% of hospitalized STEMI patient.[4]
  • Using smaller combined doses of vasopressors and inotropes is preferable over a single agent used at higher doses to avoid dose-related adverse effects.[3]
  • Perform PCI within 90 minutes of initial hospital presentation.
  • Focused cardiac ultrasound (emergency echocardiography) is helpful to rule out mechanical problems when the initial ECG findings are not conclusive or when the cardiogenic shock occurs with the first non anterior MI.[5]
  • Echocardiography should be performed early before PCI unless the diagnosis is extensive anterior MI and the patient is undergoing prompt percutaneous coronary intervention (PCI).[5]
  • Transfer the STEMI patients with cardiogenic shock to PCI irrespective to time delay from time of presentation.
  • Clopidogrel should be stopped till after angiography.
  • Use IABP when there is rapid deterioration of hemodynamic paramaters, while the on vasopressors and inotropic support.
  • Use IABP with rapid initiation of Thrombolytics < 30 min prior transfer, when there is anticipated very long delay in transfer, low risk of fibrinolysis and MI symptoms > 3 hours.
  • Use the fibrinolytic agents combined with vigorous vasopressor and IABP.

Don'ts

  • Donot give negative inotropic medications (Ca channel blocker-β Blockers)
  • Do not routinely use an intraaortic balloon pump (IABP)in all MI patients complicated with cardiogenic shock (CS), especially when there is no mechanical complications (VSD,MVR) and when the patient is scheduled for revascularization intervention.
  • Avoid fibrinolytics in NSTEMI as it is non beneficial.[6]
  • Lidocaine should not be used in ventricular arrythmia, and if used must be with the lowest dose.


References

  1. Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  2. Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  3. 3.0 3.1 Overgaard, CB.; Dzavík, V. (2008). "Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease". Circulation. 118 (10): 1047–56. doi:10.1161/CIRCULATIONAHA.107.728840. PMID 18765387. Unknown parameter |month= ignored (help)
  4. Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 Reynolds, HR.; Hochman, JS. (2008). "Cardiogenic shock: current concepts and improving outcomes". Circulation. 117 (5): 686–97. doi:10.1161/CIRCULATIONAHA.106.613596. PMID 18250279. Unknown parameter |month= ignored (help)
  6. Anderson, HV.; Cannon, CP.; Stone, PH.; Williams, DO.; McCabe, CH.; Knatterud, GL.; Thompson, B.; Willerson, JT.; Braunwald, E. (1995). "One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction". J Am Coll Cardiol. 26 (7): 1643–50. PMID 7594098. Unknown parameter |month= ignored (help)

Template:WH Template:WS